Using the power of advanced AI and Machine
Learning fused with diverse data sources,
PRiiMO personalizes and optimizes your cancer
PRiiMO has developed a digital platform for both patients
and their physicians that uses AI-based precision
medicine engine to personalize cancer treatment plans.
Our data analytics and actionable insights are
based on an intelligent combination of diverse data
sources drawn from medical records, labs, genomics,
imaging, pathology, biometrics and patient behavior.
PRiiMO selected prostate cancer as its first disease domain
serving urologists and their patients, while building a
comprehensive multi-source data asset for prostate cancer.
Reduce the harmful consequences of unnecessary invasive procedures
Improve survival rates
and quality of life
Enhance clinical decision-making and reduce treatment costs
A multidisciplinary team of oncologists, urologists, radiologists, data scientists
and entrepreneurs focused on the monitoring & treatment and of prostate cancer.
A seasoned executive in companies developing top-notch technologies, Amit brings proven leadership track record of management, business development and marketing. Prior to Cofounding PRiiMO, Amit served as Head of Program at IAI (Israel Aerospace Industries), Director of Business Development at Discretix (acquired by ARM), with previous positions at Texas Instruments, PowerDsine and LSI Logic. Amit holds a B.Sc. degree in electrical engineering and an MBA, both from Tel Aviv University.
A highly experienced CTO, Alon has co-founded multiple startups and has provided strategic advice to many small and mid-sized ventures. He has designed and lead development of software products that have won over 10 international awards. He has invented multiple patented technologies. Alon holds a B.Sc. in Information Technology from UNSW.
Prof. Stricker is considered a global Key Opinion leader in Prostate Cancer. Prof. Stricker serves as the Chairman of the Department of Urology as well as the Director of the Prostate Cancer Centre at St Vincent’s Hospital in Sydney. Prof. Stricker has established a prostate cancer repository that has collected clinical data and prostate cancer tissue samples for over 13,000 men, one of the largest prostate cancer repositories in the world.
Associate Professor Yaxley has a urological practice which is sub-specialised to the treatment of prostate cancer. A/Prof Yaxley has performed more than 3000 radical prostatectomy operations and over 1000 brachytherapy procedures. A/Prof Yaxley has over 90 peer reviewed publications and has an active interest in prostate cancer research. He was a co-investigator in the randomised open verses robotic radical prostatectomy trial at the Royal Brisbane Hospital, published in the Lancet. A/Prof Yaxley’s current interests include research into newer staging and diagnostics techniques for prostate cancer, including prostate MRI and PET PSMA scans
Laurence Klotz is a Professor of Surgery at the University of Toronto. He holds the Sunnybrook Chair of Prostate Cancer Research, is the Chairman of the World Uro-Oncology Federation, was the Founding Editor-in-Chief of both the Canadian Journal of Urology and the Canadian Urology Association Journal, and is now Editor Emeritus of the CUAJ. He was the founder and is chairman of the Canadian Urology Research Consortium (CURC). He is the chair of the SIU International Research Office (uCARE).
Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology.
Dr. Klotz is a widely published uro-oncologist with over 450 publications and 6 books. His main research interest has been prostate cancer. He is the Associate Editor of the Journal of Urology, responsible for Prostate Cancer. He is an honorary member of the AUA and Chinese Urological Association, and fellow of the AAGUS.
Dr. Klotz has led many research studies in prostate cancer, including basic research studies of the role of micronutrients and diet in prostate cancer prevention, and clinical studies in every facet of prostate cancer. He has maintained a basic research laboratory for 30 years. His work has led to several patents and a biotech company. His clinical research interests have been in the areas of active surveillance, image targeted therapy, and androgen deprivation therapy.
He received the Order of Canada, Canada’s highest civilian award (2015). Other awards include the Queen’s Jubilee Medal for meritorious public service (2013), the University of Toronto Lister Prize (2014), the Harold Warwick Prize (Canadian Cancer Society, 2014), the Society of Urologic Oncology Medal (2014), the Richard Williams Award (AUA 2016), the Dean’s Lifetime Achievement Award (University of Toronto, 2017), the Canadian Urological Association Lifetime Achievement Award in 2019, and the Huggins Medal from the SUO in 2019.
Dr Ronald Shnier is a practising Radiologist specialising in MSK and Prostate Imaging and he is also the Chief Medical Officer of I-MED Radiology Network. Dr Shnier completed his Radiology training at Royal Prince Alfred Hospital and undertook a MSK fellowship at UCLA in 1991.
Dr Shnier was the co-author of the OMERACT scoring system used internationally in the assessment of Rheumatoid Arthritis and he is currently participating in an international trial looking at lymph node spread in Prostate Cancer, as well as the role of MRI in active surveillance.
His other relevant positions include non-executive director of the Permira I-MED board, Director of Artificial intelligence for I-MED and Vice president of ADIA (previous past president). Previously Dr Shnier was the General Manager of Mayne Diagnostic Imaging and the Clinical Director of the Neuroscience Research Centre in Randwick.
Chairman, Department of Urology, CHU of Lille, Lille University 59000 Lille, France
Main topic of expertise and publications are in the field of prostate cancer.
Localized prostate cancer : This topic includes natural history, morphogenesis, treatments and relevance of prostate zonal anatomy to the development of prostate cancer. Investigator in prostate MRI evaluation including validation, biopsy indication and partial treatment. Investigator in HIFU partial gland ablation studies.
Participant in international Global Action Program 3 on Active surveillance with Movember.
Main investigator of the french participation of the ERSPC (European Randomized Study of Prostate Cancer Screening)
Dr. Ponsky is the Leo and Charlotte Goldberg Chair of Advanced Surgical Therapies and Master Clinician in Urologic Oncology at University Hospitals Cleveland Medical Center. He is also the Chairman of the department of Urology and Urology Institute at University Hospitals Cleveland Medical Center. In addition, Dr. Ponsky is a professor of urology at Case Western Reserve University School of Medicine.
Dr. M.J.V Scheltema. After completing medical school at the University of Amsterdam he specialized in prostate cancer care by combining clinical Urology with research. In his PhD he focused on focal therapy for localized prostate cancer. He now holds a post doctorate position at the Garvan Institute and St. Vincent’s Prostate Cancer Centre on various prostate cancer research lines involving multiparametric MRI, PSMA PET CT, immunology, focal therapy, robotic surgery and active surveillance.
Dr James Thompson is a Urologic Surgeon trained at St Vincents Hospital then University College London Hospital. He performs surgery at St Vincents, St George and Hurstville Hopsitals in Sydney, Australia. He has sub-speciality expertise in the diagnosis and management prostate and bladder cancer, including MRI, PSMA, fusion-targeted biopsy, active surveillance, focal therapy and robotic surgery. He is an executive committee member of the APCRC and ANZUP, a senior research fellow at the Garvan Institute of Medical Research and Conjoint Senior Lecturer at University of NSW. He has co-authored over 40 publications in prostate cancer and is currently an investigator on more than 20 multicentre research studies and clinical trials in prostate and bladder cancer.
Prostate cancer is the second most frequent cancer in men and the fifth leading cause of death worldwide. Most prostate cancer patients have several treatment pathways to consider. Immediate treatment carries the risk of severe side effects such as incontinence or erectile dysfunction.
However, in most cases patients only require Active Surveillance and can delay treatment for many years. Unfortunately, only 30% of all patients diagnosed are placed on Active Surveillance, while the majority often perform unnecessary and harmful treatment.
Choosing a treatment option is complicated and can vary greatly based on the stage of the cancer, the patient’s age, overall health and life expectancy, as well as personal preferences.
PRiiMO’s mission is to personalize the prevention, screening, diagnosis, monitoring, treatment and post-treatment of these patients, minimizing risk and treatment costs, and maximizing the number of normal life years.
PRiiMO has embarked on a journey to define and create the world’s most comprehensive database, providing patient-specific monitoring and treatment of prostate cancer. PRiiMO optimizes the patient pathway by applying advanced AI and Machine Learning technologies to patient-specific data, fusing the full range of personal and lifestyle information, genomics, biomarkers, test results and imaging.
We are actively growing our team and looking for those who want to change the way
cancer is treated and make an unprecedent impact on patients’ lives.
We’re seeking a super talented Chief Data Scientist.
This person will build the Machine Learning layer that will collect the various medical parameters and biomarkers, and fuse them together to create insights for an optimized monitoring and treatment plan for the patient.
You are expected to lead all aspects of PRiiMO’s Machine Learning R&D; understand and refine goals, define and implement algorithms from prototypes to full deployment, create insights and forecasts from medical bio-markers and big data, handle data management operations and software engineering, as well as build the Machine Learning team and manage it.
You will “bootstrap” all research and engineering processes, and work closely with our CTO.
Please fill in the form below and we’ll be happy to be in touch.